Drug News

Ono Pharmaceutical Collaborates with EVQLV for AI-Powered Antibody Development

Ono Pharmaceutical Co., Ltd., a prominent Japanese pharmaceutical company, has announced a strategic collaboration with EVQLV, INC, based in Miami, Florida, to leverage EVQLV’s Artificial Intelligence (AI)-powered Antibody Design Engine for the generation of novel antibodies.

The collaboration aims to develop innovative antibody drugs against multiple therapeutic targets selected by Ono.

Key Highlights:

  • Collaboration Agreement: Ono and EVQLV have entered into a discovery collaboration agreement to utilize EVQLV’s proprietary AI-powered Antibody Design Engine for the creation of therapeutic antibody designs.
  • AI-Powered Antibody Design: EVQLV’s technology will be employed to generate therapeutic antibody designs against multiple targets specified by Ono, streamlining the process of antibody drug discovery.
  • Research Funding: Ono will provide research funding to EVQLV during the research period. Success-based research milestone payments will also be made to EVQLV.
  • Option Rights: Ono retains the option rights to exclusively and globally develop and commercialize the generated antibody drug candidates.

Expert Statements:

  • Dr. Toichi Takino, Senior Executive Officer / Executive Director, Discovery and Research of Ono: “We are very pleased to collaborate with EVQLV having its proprietary AI-powered Antibody Design Engine. We expect that the EVQLV’s AI- technology will enable us to create novel antibody candidates against multiple targets more promptly and effectively.”
  • Andrew Satz, CEO and Co-founder of EVQLV: “At EVQLV, our mission is to make AI easily accessible to researchers in order to positively impact the odds of success in drug discovery. We are honored to be working alongside the scientific and drug development experts at Ono, who have the ability to leverage our AI-designed antibodies and deliver breakthrough options for patients in need.”

Shared Goals and Commitments:

  • Biologics and Antibody Drugs: Ono emphasizes its commitment to biologics, including antibody drugs, to address unmet medical needs across various diseases.
  • Accelerated Drug Discovery: The collaboration aims to accelerate efforts in antibody drug discovery against multiple targets, anticipating prompt and effective outcomes through EVQLV’s AI technology.

This collaboration signifies the merging of Ono’s expertise in identifying unique targets with EVQLV’s cutting-edge AI technology, with the shared objective of advancing drug discovery and delivering impactful solutions for patients.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker